US 11,986,292 B2
Insulin pump based expert system
Michael Blomquist, Blaine, MN (US)
Assigned to Tandem Diabetes Care, Inc., San Diego, CA (US)
Filed by Tandem Diabetes Care, Inc., San Diego, CA (US)
Filed on Apr. 7, 2022, as Appl. No. 17/715,735.
Application 13/465,570 is a division of application No. 11/755,480, filed on May 30, 2007, granted, now 8,221,345, issued on Jul. 17, 2012.
Application 17/715,735 is a continuation of application No. 16/560,555, filed on Sep. 4, 2019, granted, now 11,576,594.
Application 16/560,555 is a continuation of application No. 15/830,415, filed on Dec. 4, 2017, granted, now 11,298,053, issued on Apr. 12, 2022.
Application 15/830,415 is a continuation in part of application No. 14/187,414, filed on Feb. 24, 2014, granted, now 9,833,177, issued on Dec. 5, 2017.
Application 14/187,414 is a continuation of application No. 13/465,570, filed on May 7, 2012, granted, now 8,657,779, issued on Feb. 25, 2014.
Prior Publication US 2022/0225906 A1, Jul. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/145 (2006.01); A61B 5/00 (2006.01); A61M 5/172 (2006.01); G16H 10/20 (2018.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); A61M 5/142 (2006.01)
CPC A61B 5/14532 (2013.01) [A61B 5/4839 (2013.01); A61B 5/7475 (2013.01); A61M 5/1723 (2013.01); G16H 10/20 (2018.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); A61B 5/7275 (2013.01); A61B 2560/045 (2013.01); A61M 2005/14208 (2013.01); A61M 2205/3561 (2013.01); A61M 2205/52 (2013.01); A61M 2230/201 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of diabetes therapy, comprising:
delivering insulin to a user with an insulin pump;
receiving sensor glucose data representative of a blood glucose level of a user from a continuous glucose monitor via a wireless connection;
monitoring the sensor glucose data from the continuous glucose monitor while the insulin pump is delivering a basal rate of insulin to the user;
comparing the sensor glucose data to a target low glucose level;
determining a rate of change of the blood glucose level of the user from the sensor glucose data;
generally continuously monitoring the rate of change;
determining based on the generally continuous monitoring of the rate of change that, although the sensor glucose data does not indicate that the glucose level of the user is below the target low glucose level that the rate of change indicates that the glucose level of the user is at risk of going below the target low glucose level due to the basal rate of insulin being delivered to the user;
providing a notification indicating the risk of going below the target low glucose level; and
reducing a basal rate of insulin being delivered to the user in response to the risk of going below the target low glucose level.